NGN Capital leads €33m series-D round for NOXXON Pharma AG
NGN Capital has led a €33m series-D round in NOXXON Pharma. NGN is a new investor and was joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others.
More on DACH
Hg’s MEDIFOX sale launch draws large-cap sponsor interest
Hg acquired the software platform for care providers in 2018 from ECM Equity Capital Management
Silver Investment forms continuation vehicle for PTF
Selling investors have made returns of 6x their original investment in the precision parts producer
Synthesis Capital holds USD 300m final close for debut fund
Costa Yiannoulis and David Welch spoke to Unquote about the food technology and alternative protein VC's strategy
Perusa to exit Müpro in SBO to IK
Management of the German industrial fixings supplier will reinvest with a minority stake
Latest News
FSN Capital acquires Epista Life Sciences
The GP said it will pursue a buy-and-build strategy in the life science IT services sector
Advent Life Sciences hires three partners
Dominic Schmidt is based in the UK, while Satish Jindal and Katrine Bosley join in the US
Five Arrows kicks off Laf Santé sale
Five Arrows has owned a majority stake in the France-based low-cost pharmacy chain since 2016
Hg’s MEDIFOX sale launch draws large-cap sponsor interest
Hg acquired the software platform for care providers in 2018 from ECM Equity Capital Management